Elena Ruggieri

Elena Ruggieri

Auto-generated profile, based on publicly available information

Elena Ruggieri

Division of Genetics and Cell Biology, Tissue Regeneration and Homeostasis Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
GCGiorgia Careccia
Giorgia Careccia
MSMarielle Saclier
Marielle Saclier
MTMario Tirone
Mario Tirone
ERElena Ruggieri
Elena Ruggieri
EPElisa Principi
Elisa Principi
EVEmilie Vénéreau
Emilie Vénéreau
The redox-sensitive HMGB1 protein is a functional link between oxidative stress and persistent inflammation in muscular dystrophies.

1 August 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RBR Alessia Battista
R Alessia Battista
MRMassimo Resnati
Massimo Resnati
CFCecilia Facchi
Cecilia Facchi
ERElena Ruggieri
Elena Ruggieri
FCFloriana Cremasco
Floriana Cremasco
EMEnrico Milan
Enrico Milan
To cope with intrinsic and environmental stress, cancer cells rely on adaptive pathways more than non-transformed counterparts. Such non-oncogene addiction offers new therapeutic targets and strategies to overcome chemoresistance. In an attempt to study the role of adaptive pathways in acquired drug resistance in carcinoma cells, we devised a model of in vitro conditioning to three standard chemotherapeutic agents, cisplatin, 5-fluorouracil, and docetaxel, from the epithelial cancer cell line, HEp-2, and investigated the mechanisms underlying reduced drug sensitivity. We found that triple-resistant cells suffered from higher levels of oxidative stress, and showed heightened anti-stress responses, including the antioxidant Nrf2 pathway and autophagy, a conserved pleiotropic homeostatic strategy, mediating the clearance of aggregates marked by the adapter p62/SQSTM1. As a result, re-administration of chemotherapeutic agents failed to induce further accumulation of reactive oxygen species and p62. Moreover, autophagy proved responsible for chemoresistance through the avoidance of p62 accumulation into toxic protein aggregates. Indeed, p62 ablation was sufficient to confer resistance in parental cells, and genetic and pharmacological autophagic inhibition restored drug sensitivity in resistant cells in a p62-dependent manner. Finally, exogenous expression of mutant p62 lacking the ubiquitin- and LC3-binding domains, required for autophagic engulfment, increased chemosensitivity in TDR HEp-2 cells. Altogether, these findings offer a cellular system to investigate the bases of acquired chemoresistance of epithelial cancers and encourage challenging the prognostic and antineoplastic therapeutic potential of p62 toxicity.